KR20060005333A - 특정의 신규한 이미다조피리딘 및 그의 용도 - Google Patents

특정의 신규한 이미다조피리딘 및 그의 용도 Download PDF

Info

Publication number
KR20060005333A
KR20060005333A KR1020057002263A KR20057002263A KR20060005333A KR 20060005333 A KR20060005333 A KR 20060005333A KR 1020057002263 A KR1020057002263 A KR 1020057002263A KR 20057002263 A KR20057002263 A KR 20057002263A KR 20060005333 A KR20060005333 A KR 20060005333A
Authority
KR
South Korea
Prior art keywords
imidazo
pyridin
bromo
phenyl
phenoxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020057002263A
Other languages
English (en)
Korean (ko)
Inventor
헨리크 요한슨
카롤리나 라비츠
그리고리오스 니키티디스
페터 쇠
페터 스토름
Original Assignee
아스트라제네카 아베
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 아스트라제네카 아베 filed Critical 아스트라제네카 아베
Publication of KR20060005333A publication Critical patent/KR20060005333A/ko
Withdrawn legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • A61K31/41621,2-Diazoles condensed with heterocyclic ring systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/02Nasal agents, e.g. decongestants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
KR1020057002263A 2002-08-14 2003-08-13 특정의 신규한 이미다조피리딘 및 그의 용도 Withdrawn KR20060005333A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE0202462-8 2002-08-14
SE0202462A SE0202462D0 (sv) 2002-08-14 2002-08-14 Novel use

Publications (1)

Publication Number Publication Date
KR20060005333A true KR20060005333A (ko) 2006-01-17

Family

ID=20288750

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020057002263A Withdrawn KR20060005333A (ko) 2002-08-14 2003-08-13 특정의 신규한 이미다조피리딘 및 그의 용도

Country Status (18)

Country Link
US (1) US7410966B2 (enExample)
EP (1) EP1539759B1 (enExample)
JP (1) JP2006503010A (enExample)
KR (1) KR20060005333A (enExample)
CN (1) CN100358893C (enExample)
AT (1) ATE370138T1 (enExample)
AU (1) AU2003251272A1 (enExample)
BR (1) BR0313461A (enExample)
CA (1) CA2495511A1 (enExample)
DE (1) DE60315674T2 (enExample)
ES (1) ES2290538T3 (enExample)
IL (1) IL166413A0 (enExample)
MX (1) MXPA05001581A (enExample)
NO (1) NO20051265L (enExample)
NZ (1) NZ538156A (enExample)
SE (1) SE0202462D0 (enExample)
WO (1) WO2004016611A1 (enExample)
ZA (1) ZA200500887B (enExample)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA06011021A (es) * 2004-03-25 2007-04-13 Johnson & Johnson Compuestos de imidazol.
US7714130B2 (en) 2004-06-17 2010-05-11 Wyeth Processes for preparing gonadotropin releasing hormone receptor antagonists
CN101006078A (zh) 2004-06-17 2007-07-25 惠氏公司 促性腺素释放激素受体拮抗剂
US7799778B1 (en) * 2005-01-12 2010-09-21 Alcon, Inc. 5-substituted 2-aminopyridine analogs for treating allergic and inflammatory diseases
KR20060087386A (ko) 2005-01-28 2006-08-02 주식회사 대웅제약 신규 벤조이미다졸 유도체 및 이를 함유하는 약제학적조성물
US7538113B2 (en) 2005-02-18 2009-05-26 Wyeth 4-substituted imidazo[4,5-c]pyridine antagonists of gonadotropin releasing hormone receptor
US7582634B2 (en) 2005-02-18 2009-09-01 Wyeth 7-substituted imidazo[4,5-c]pyridine antagonists of gonadotropin releasing hormone receptor
US7534796B2 (en) 2005-02-18 2009-05-19 Wyeth Imidazo[4,5-b]pyridine antagonists of gonadotropin releasing hormone receptor
US7531542B2 (en) 2005-05-18 2009-05-12 Wyeth Benzooxazole and benzothiazole antagonists of gonadotropin releasing hormone receptor
US7582636B2 (en) 2005-05-26 2009-09-01 Wyeth Piperazinylimidazopyridine and piperazinyltriazolopyridine antagonists of Gonadotropin Releasing Hormone receptor
EP1910358A2 (en) * 2005-07-14 2008-04-16 Astellas Pharma Inc. Heterocyclic janus kinase 3 inhibitors
CN101208339B (zh) 2005-08-01 2010-12-29 霍夫曼-拉罗奇有限公司 杂环苄基氨基衍生物,它们的制备以及作为药剂的应用
BRPI0503681A (pt) 2005-08-19 2007-04-10 Fundacao Oswaldo Cruz compostos azóis usados como agentes tuberculostáticos e leishmanicidas, composições farmacêuticas contendo os mesmos, uso das respectivas composições farmacêuticas no tratamento ou inibição de doenças, bem como método de tratamento ou inibição de doenças
AR057525A1 (es) * 2005-10-03 2007-12-05 Astrazeneca Ab Compuestos inhibidores selectivos de gsk3 y un proceso para su preparacion
AR055669A1 (es) * 2005-10-03 2007-08-29 Astrazeneca Ab Derivados de 3h - imidazo[4, 5 -b]piridina como inhibidores selectivos de gsk3, metodos e internediarios para su preparacion, composiciones farmaceuticas que los contienen y su uso para la elaboracion de un medicamento para el tratamiento de enfermedades neurodegenerativas y mentales.
EP1954287B2 (en) 2005-10-31 2016-02-24 Merck Sharp & Dohme Corp. Cetp inhibitors
US8088761B2 (en) 2005-12-22 2012-01-03 Cancer Research Technology Limited Enzyme inhibitors
CA2637392A1 (en) * 2006-01-23 2007-07-26 Crystalgenomics, Inc. Imidazopyridine derivatives inhibiting protein kinase activity, method for the preparation thereof and pharmaceutical composition containing same
ITMI20061581A1 (it) * 2006-08-04 2008-02-05 Univ Bari Ligandi del recettore beta-3 adrenergico e loro uso in terapia
US8153792B2 (en) * 2007-02-13 2012-04-10 Ab Science Process for the synthesis of 2-aminothiazole compounds as kinase inhibitors
WO2008121063A1 (en) * 2007-03-30 2008-10-09 Astrazeneca Ab New imidazo[ 4,5-b]pyridine-7-carboxamides 704
WO2008121064A1 (en) * 2007-03-30 2008-10-09 Astrazeneca Ab New imidazo[4,5-b]pyridine-6-halo-7-aryl/heteroaryl compounds 705
WO2009001021A1 (en) * 2007-06-26 2008-12-31 Chroma Therapeutics Ltd. Imidazopyridine derivatives useful as enzyme inhibitors for the treatment of cell proliferative and autoimmune diseases
CN102264745B (zh) * 2008-11-10 2015-07-22 财团法人卫生研究院 作为酪胺酸激酶抑制剂的稠合双环及多环嘧啶化合物
TWI461425B (zh) * 2009-02-19 2014-11-21 Janssen Pharmaceuticals Inc 作為伽瑪分泌酶調節劑之新穎經取代的苯并唑、苯并咪唑、唑并吡啶及咪唑并吡啶衍生物類
AU2011308256B2 (en) * 2010-09-28 2015-08-20 Daewoong Pharmaceutical Co., Ltd. Novel method of preparing benzoimidazole derivatives
WO2013116291A1 (en) * 2012-01-30 2013-08-08 Cephalon, Inc. Imidazo [4, 5 - b] pyridine derivatives as alk and jak modulators for the treatment of proliferative disorders
WO2013153539A1 (en) 2012-04-13 2013-10-17 Glenmark Pharmaceuticals S.A. Tricyclic compounds as tec kinase inhibitors
CN103724331A (zh) * 2012-10-11 2014-04-16 韩冰 一类治疗脑性瘫痪的化合物及其用途
CN103800328A (zh) * 2012-11-07 2014-05-21 韩冰 一类治疗神经退行性疾病的化合物及其用途
GB201302927D0 (en) 2013-02-20 2013-04-03 Cancer Therapeutics Crc Pty Ltd Compounds
WO2014175370A1 (ja) * 2013-04-25 2014-10-30 塩野義製薬株式会社 ピロリジン誘導体およびそれらを含有する医薬組成物
MX392373B (es) 2013-10-25 2025-03-24 Pharmacyclics Llc Uso de ibrutinib en el tratamiento de enfermedad injerto contra huesped cronica
WO2016034673A1 (en) 2014-09-03 2016-03-10 Ctxt Pty Ltd Tetrahydroisoquinoline derived prmt5-inhibitors
US10005792B2 (en) 2014-09-03 2018-06-26 Ctxt Pty. Ltd. Aminoindane-, aminotetrahydronaphthalene- and aminobenzocyclobutane-derived PRMT5-inhibitors
GB201415573D0 (en) 2014-09-03 2014-10-15 Cancer Therapeutics Crc Pty Ltd Compounds
BR112017016428B1 (pt) 2015-02-02 2023-10-24 Kancera Ab Composto ou sal farmaceuticamente aceitável, composição farmacêutica, e, uso de um composto ou sal farmaceuticamente aceitável
CN108135904A (zh) 2015-08-31 2018-06-08 药品循环有限责任公司 用于治疗多发性骨髓瘤的btk抑制剂组合
GB201604031D0 (en) 2016-03-09 2016-04-20 Ctxt Pty Ltd Compounds
GB201604022D0 (en) 2016-03-09 2016-04-20 Ctxt Pty Ltd Compounds
GB201604030D0 (en) 2016-03-09 2016-04-20 Ctxt Pty Ltd Compounds
GB201604027D0 (en) 2016-03-09 2016-04-20 Ctxt Pty Ltd Compounds
GB201604029D0 (en) 2016-03-09 2016-04-20 Ctxt Pty Ltd Compounds
GB201604020D0 (en) 2016-03-09 2016-04-20 Ctxt Pty Ltd Compounds
CN109563092B (zh) * 2016-07-11 2021-09-14 坎塞拉有限公司 可用作哺乳动物酪氨酸激酶ror1活性的抑制剂的2-苯基咪唑并[4,5-b]吡啶-7-胺衍生物
US11660303B2 (en) 2016-07-11 2023-05-30 Kancera Ab 2-phenylimidazo[4,5-b]pyridin-7-amine derivates useful as inhibitors of mammalian tyrosine kinase ROR1 activity
WO2018085731A2 (en) 2016-11-03 2018-05-11 Juno Therapeutics, Inc. Combination therapy of a t cell therapy and a btk inhibitor
EP3787751A1 (en) 2018-05-03 2021-03-10 Juno Therapeutics, Inc. Combination therapy of a chimeric antigen receptor (car) t cell therapy and a kinase inhibitor
BR112022016400A2 (pt) 2020-02-18 2022-10-25 Bayer Ag Compostos inovadores de heteroaril-triazol como pesticidas
CN113582988B (zh) * 2020-04-30 2025-09-09 正大天晴药业集团股份有限公司 吡啶并环类化合物及其医药用途
WO2023220655A1 (en) 2022-05-11 2023-11-16 Celgene Corporation Methods to overcome drug resistance by re-sensitizing cancer cells to treatment with a prior therapy via treatment with a t cell therapy

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3985891A (en) * 1973-02-03 1976-10-12 Boehringer Ingelheim Gmbh 2-Phenyl-imidazo (4,5-b)pyridines and salts thereof
DE3037464A1 (de) 1980-10-03 1982-05-19 Dr. Karl Thomae Gmbh, 7950 Biberach 6-hydroxy-2-phenyl-imidazo 4,5-b zu pyridine, ihre herstellung und diese sie enthaltende arzneimittel
US5296591A (en) * 1990-12-31 1994-03-22 Fujisawa Pharmaceutical Co., Ltd. Trifluoromethylketone derivatives, processes for preparation thereof and use thereof
WO2001096336A2 (en) * 2000-06-14 2001-12-20 Warner-Lambert Company 6,5-fused bicyclic heterocycles
AU2002220276A1 (en) * 2000-12-12 2002-06-24 Neurogen Corporation Spiro(isobenzofuran-1,4'-piperidin)-3-ones and 3h-spiroisobenzofuran-1,4'-piperidines

Also Published As

Publication number Publication date
ES2290538T3 (es) 2008-02-16
BR0313461A (pt) 2005-07-05
DE60315674T2 (de) 2008-06-19
ZA200500887B (en) 2006-02-22
US20050261333A1 (en) 2005-11-24
SE0202462D0 (sv) 2002-08-14
CA2495511A1 (en) 2004-02-26
US7410966B2 (en) 2008-08-12
EP1539759B1 (en) 2007-08-15
NO20051265L (no) 2005-05-12
EP1539759A1 (en) 2005-06-15
ATE370138T1 (de) 2007-09-15
JP2006503010A (ja) 2006-01-26
WO2004016611A1 (en) 2004-02-26
DE60315674D1 (de) 2007-09-27
AU2003251272A1 (en) 2004-03-03
MXPA05001581A (es) 2005-04-25
CN100358893C (zh) 2008-01-02
CN1684964A (zh) 2005-10-19
IL166413A0 (en) 2006-01-15
NZ538156A (en) 2006-09-29

Similar Documents

Publication Publication Date Title
US7410966B2 (en) Use of and some novel imidazopyridines
EP3119765B1 (en) Heteroaryl syk inhibitors
US6710047B2 (en) Phthalazines with angiogenesis inhibiting activity
JP4764823B2 (ja) キナーゼ阻害剤としての1,6−二置換アザベンゾイミダゾールの調製
JP2012514044A (ja) Rafキナーゼ阻害剤として有用なヘテロアリール化合物
JP4571944B2 (ja) 新規のピリドピラジン及びそれらのキナーゼモジュレーターとしての使用
JP2007507547A (ja) キナーゼ阻害剤としての1,7−二置換アザベンゾイミダゾールの調製
CZ20023934A3 (cs) Deriváty beta-karbolinu pro použití jako inhibitory fosfodiesterázy
MX2015004151A (es) Inhibidores del factor de diferenciacion de crecimiento-8 (gdf-8).
JP2013544256A (ja) 複素環式アミンおよびその使用
BR112020000284A2 (pt) amidas heterocíclicas de 5 membros e bicíclicas como inibidores de rock
ME01296B (me) Derivati 4-(2-amino-1-hidroksietil) fenol kao agonisti beta-2 adrenergičkih receptora
BRPI0806811A2 (pt) derivados de purina
CA2905751A1 (en) Novel compounds and compositions for inhibition of fasn
EP2818472A1 (en) Imidazo[4,5-c]pyridine and pyrrolo[3,2-c]pyridine compounds as G-protein-coupled receptor kinase 5 (GRK5) modulators
US20230089368A1 (en) Polyaromatic urea derivatives and their use in the treatment of muscle diseases
CN106459043A (zh) 萘啶二酮衍生物
AU2015263013A1 (en) Fused triazole derivatives as phosphodiesterase 10A inhibitors
JP5126830B2 (ja) ピロロ[3,2−c]ピリジン誘導体及びその製造方法
TW202321232A (zh) 小分子sting拮抗劑
CN118159535A (zh) 小分子sting拮抗剂
JP7688242B1 (ja) 3-フェニルプロピルアミン誘導体
CN103228656B (zh) 3-取代基-6-(吡啶基甲氧基)-吡咯并吡啶化合物
ES2371928T3 (es) Nuevos aza-heterociclos que actúan como inhibidores de la quinasa.
WO2014132220A1 (en) Solid forms of bicyclic heterocyclic derivatives as pdgf receptor mediators

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20050207

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PC1203 Withdrawal of no request for examination
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid